2025
Resistance to tuberculin skin test/interferon-gamma release assay conversion among highly TB exposed, HIV infected goldminers in South Africa
Ntshiqa T, Velen K, Ginindza S, Nhlangulela L, Charalambous S, Hawn T, Churchyard G, Boom W, Chihota V, Wallis R. Resistance to tuberculin skin test/interferon-gamma release assay conversion among highly TB exposed, HIV infected goldminers in South Africa. PLOS ONE 2025, 20: e0318819. PMID: 40343976, PMCID: PMC12063869, DOI: 10.1371/journal.pone.0318819.Peer-Reviewed Original ResearchConceptsIsoniazid preventive therapyTuberculin skin testCD4 countQFT-PlusAssociated with lower CD4 countsTST responseQuantiFERON-TB Gold PlusBody mass index >Median CD4 countLow CD4 countExposure to TBRates of HIVLongitudinal cohort studyMedian ageTST/IGRAAntiretroviral treatmentMedian timePreventive therapySkin testFollow-upCohort studyLogistic regressionHIVMonthsAssay conversionReal-world outcomes with T-VEC in patients with anti-PD-1 resistant in-transit disease from melanoma and Merkel cell carcinoma
Su D, McNamara M, Kaszycki M, Frey A, Ishizuka J, Costa P, Tran T, Kluger H, Clune J, Weiss S, Olino K. Real-world outcomes with T-VEC in patients with anti-PD-1 resistant in-transit disease from melanoma and Merkel cell carcinoma. Surgical Oncology Insight 2025, 2: 100120. DOI: 10.1016/j.soi.2024.100120.Peer-Reviewed Original ResearchMerkel cell carcinomaMerkel cell carcinoma casesT-VECCell carcinomaMedian numberAnti-PD-1 blockadeStage IIIB-IV melanomaAdvanced Merkel cell carcinomaIn-transit melanomaIn-transit diseaseICI therapyTalimogene laherparepvecAdvanced melanomaCancer immunotherapyMetastatic sitesPartial responseIn-transitRegional metastasesMedian ageGrade 3Adverse eventsTreatment cyclesDisease progressionMelanomaPatientsArtificial Intelligence-Enhanced Perfusion Scoring Improves the Diagnostic Accuracy of Myocardial Perfusion Imaging.
Miller R, Kavanagh P, Lemley M, Liang J, Sharir T, Einstein A, Fish M, Ruddy T, Kaufmann P, Sinusas A, Miller E, Bateman T, Dorbala S, Di Carli M, Hayes S, Friedman J, Berman D, Dey D, Slomka P. Artificial Intelligence-Enhanced Perfusion Scoring Improves the Diagnostic Accuracy of Myocardial Perfusion Imaging. Journal Of Nuclear Medicine 2025, jnumed.124.268079. PMID: 39978815, DOI: 10.2967/jnumed.124.268079.Peer-Reviewed Original ResearchObstructive coronary artery diseaseCoronary artery diseaseArea under the receiver operating characteristic curveMyocardial perfusion imagingPerfusion scoreDetection of obstructive coronary artery diseaseDiagnostic accuracy of myocardial perfusion imagingPerfusion imagingAccuracy of myocardial perfusion imagingInvasive coronary angiographyCohort of patientsHighest area under the receiver operating characteristic curveLeft main coronary arteryReceiver operating characteristic curveStress TPDDeep learningObstructive CADMedian ageCoronary angiographyArtificial intelligenceDiagnostic performanceDiagnostic accuracyArtery diseaseAI predictionsCoronary arteryPilot study evaluating duplex sequencing of urinary DNA as a biomarker for recurrence in non-muscle invasive bladder cancer.
Ghali F, Blaha O, Lam H, Kennedy S, Wright J. Pilot study evaluating duplex sequencing of urinary DNA as a biomarker for recurrence in non-muscle invasive bladder cancer. Journal Of Clinical Oncology 2025, 43: 865-865. DOI: 10.1200/jco.2025.43.5_suppl.865.Peer-Reviewed Original ResearchNon-muscle invasive bladder cancerInvasive bladder cancerVariant allele fractionUrinary DNAIntravesical therapyBladder cancerPathogenic variantsTransurethral resection of bladder tumorMedian time to recurrenceResection of bladder tumorNext-generation sequencingDetection of recurrenceTime to recurrenceTime to relapseRecurrence of tumorBiomarkers of recurrencePilot studyTransurethral resectionBladder tumorsMedian ageRecurrenceAllele fractionUrine samplesTumorBiomarkersAsciminib plus dasatinib and prednisone for Philadelphia chromosome–positive acute leukemia
Luskin M, Murakami M, Keating J, Flamand Y, Winer E, Garcia J, Stahl M, Stone R, Wadleigh M, Jaeckle S, Hagopian E, Weinstock D, Liegel J, McMasters M, Wang E, Stock W, DeAngelo D. Asciminib plus dasatinib and prednisone for Philadelphia chromosome–positive acute leukemia. Blood 2025, 145: 577-589. PMID: 39374521, DOI: 10.1182/blood.2024025800.Peer-Reviewed Original ResearchConceptsAcute leukemiaPhiladelphia chromosome-positive acute leukemiaRecommended phase 2 dosePh+ acute lymphoblastic leukemiaHematopoietic stem cell transplantationDe novo ALLHematologic remission rateLymphoid blast crisisMaximum tolerated doseStem cell transplantationPhase 1 studyChronic myeloid leukemiaMulticolor flow cytometryAcute lymphoblastic leukemiaVaso-occlusive eventsCytogenetic remissionBlast crisisSymptomatic pancreatitisTolerated doseRemission ratePh+ ALLCell transplantationMedian ageEnzyme elevationLymphoblastic leukemiaAssociation of Causative Pathogens With Acute Kidney Injury in Adult Patients With Community-Onset Sepsis
Pant P, Chihara S, Krishnamoorthy V, Treggiari M, Messina J, Privratsky J, Raghunathan K, Ohnuma T. Association of Causative Pathogens With Acute Kidney Injury in Adult Patients With Community-Onset Sepsis. Critical Care Explorations 2025, 7: e1219. PMID: 39937578, PMCID: PMC11826047, DOI: 10.1097/cce.0000000000001219.Peer-Reviewed Original ResearchConceptsAcute kidney injuryOdds of acute kidney injuryDevelopment of acute kidney injuryCommunity-onset sepsisAdult patientsKidney injuryAssociated with increased odds of AKICausative pathogenPINC AI Healthcare DatabaseAcute kidney injury riskMultilevel logistic regressionGlobal Outcomes serum creatinine criteriaAssociated with decreased oddsAssociated with increased oddsSerum creatinine criteriaStage 1 AKIStage 3 AKIStage 2 AKIRetrospective cohort studyCritically ill patientsDay of admissionE. coli infectionCommunity-onsetCreatinine criteriaMedian ageMild Malformation of Cortical Development With Oligodendroglial Hyperplasia and Epilepsy
Zhan Y, Chen S, Jin Z, Zhou J, Zhang Y, Hou Q, Wang Y, Zheng G, Zheng Y. Mild Malformation of Cortical Development With Oligodendroglial Hyperplasia and Epilepsy. Neurology Genetics 2025, 11: e200240. PMID: 39902276, PMCID: PMC11790282, DOI: 10.1212/nxg.0000000000200240.Peer-Reviewed Original ResearchMild malformation of cortical developmentMalformations of cortical developmentMild malformationCase reportOligodendroglial hyperplasiaCortical developmentFavorable surgical outcomeNinety-five patientsForty-five patientsDrug-resistant epilepsyLennox-Gastaut syndromeSystematic reviewSelection of treatmentAge-dependent phenotypeRisk of biasRare entityEpileptic spasmsMedian ageSurgical outcomesHistopathological diagnosisInterictal EEGVariant statusSeizure outcomeCase seriesWest syndrome155. Long-Acting Subcutaneous Lenacapavir in People with Multi-Drug Resistant HIV-1: 3-Year Results of the CAPELLA Study
Ogbuagu O, McGowan J, Stapleton A, Wiznia A, Berger D, Creticos C, Hagins D, Osiyemi O, Sims J, Wheeler D, Wang H, Margot N, Dvory-Sobol H, Rhee M, Segal-Maurer S. 155. Long-Acting Subcutaneous Lenacapavir in People with Multi-Drug Resistant HIV-1: 3-Year Results of the CAPELLA Study. Open Forum Infectious Diseases 2025, 12: ofae631.041. PMCID: PMC11776782, DOI: 10.1093/ofid/ofae631.041.Peer-Reviewed Original ResearchInjection site reactionsCD4 cell countHIV-1 RNAHIV-1Site reactionsMultidrug resistanceGilead SciencesVirologic suppressionCell countRates of virologic suppressionMulti-drug resistant HIV-1FDA snapshot algorithmResistant HIV-1Len resistanceTreatment-experiencedVirological outcomesGrade 1/2Study drugMedian ageLenacapavirLens toleranceSafety profileLonger-term dataAdverse eventsCD4Real-world Rollout of Injectable Antiretrovirals for HIV Prevention and Treatment: Correlates of Early Adoption
Koshy L, Payne E, Barakat L, Hao R, Sureshanand S, Ornelas A, Dewan A, Meyer J. Real-world Rollout of Injectable Antiretrovirals for HIV Prevention and Treatment: Correlates of Early Adoption. Open Forum Infectious Diseases 2025, 12: ofaf029. DOI: 10.1093/ofid/ofaf029.Peer-Reviewed Original ResearchLAI-PrEPLAI-ARTSocial determinants of healthSubstance use disordersDeterminants of healthLong-actingRetrospective cohortRetrospective cohort of patientsSocial determinantsHIV preventionCohort of patientsFisher's exact testPre-exposure prophylaxisOvercome health inequitiesHealth equity lensPrEP patientsChi-square testUrban health systemMedian ageBivariate logistic regressionOral PrEPPublic health interventionsBackground DataExact testHIV treatmentRespiratory syncytial virus vaccine effectiveness among US veterans, September, 2023 to March, 2024: a target trial emulation study
Bajema K, Yan L, Li Y, Argraves S, Rajeevan N, Fox A, Vergun R, Berry K, Bui D, Huang Y, Lin H, Hynes D, Lucero-Obusan C, Schirmer P, Cunningham F, Huang G, Aslan M, Ioannou G. Respiratory syncytial virus vaccine effectiveness among US veterans, September, 2023 to March, 2024: a target trial emulation study. The Lancet Infectious Diseases 2025 PMID: 39848264, DOI: 10.1016/s1473-3099(24)00796-5.Peer-Reviewed Original ResearchRespiratory syncytial virusRespiratory syncytial virus vaccinePositive RSV testVaccine effectivenessRSV testCare encountersSecondary outcomesEmergency departmentRSV-associated hospitalisationsMedian follow-upUS Food and Drug AdministrationHealth-care useVeterans Health AdministrationRespiratory illness seasonMatched index dateElectronic health recordsLower respiratory tract diseaseRSV-related illnessFood and Drug AdministrationDepartment of Veterans Affairs Cooperative Studies ProgramVeterans Affairs Cooperative Studies ProgramCooperative Studies ProgramRSV infectionMedian ageUS DepartmentBiomarker Panels for Discriminating Risk of CKD Progression in Children.
Greenberg J, Abraham A, Xu Y, Schelling J, Coca S, Schrauben S, Wilson F, Waikar S, Vasan R, Gutierrez O, Shlipak M, Ix J, Warady B, Kimmel P, Bonventre J, Parikh C, Denburg M, Furth S. Biomarker Panels for Discriminating Risk of CKD Progression in Children. Journal Of The American Society Of Nephrology 2025 PMID: 39820177, DOI: 10.1681/asn.0000000602.Peer-Reviewed Original ResearchPlasma KIM-1CKD progressionKIM-1Alpha 1-microglobulinUrine albumin/creatinineBaseline urine protein-to-creatinine ratiosBiomarker panelRisk factorsRisk of CKD progressionAssociated with CKD progressionUrine alpha-1-microglobulinRisk group classificationProtein-to-creatinine ratioUrine protein-to-creatinine ratioClinical risk factorsChildren 6 monthsHigh-risk groupUrine KIM-1Clinically relevant biomarkersConventional risk factorsCombination of biomarkersTubular healthBaseline eGFRMedian ageEGFR declinePhenotype Spectrum of TRPM3‐Associated Disorders
Jolitz L, Helbig I, Fitzgerald M, Ruggiero S, Cohen S, Angelini C, Vallespin E, Michaud V, Gerasimenko A, Cogne B, Isidor B, Keren B, Dyment D, Heron D, Karstensen H, Cuppen I, Christodoulou J, Wilson M, Lake N, Biskup S, Syrbe S, Mori T, Becker L, Kaindl A. Phenotype Spectrum of TRPM3‐Associated Disorders. Annals Of Neurology 2025, 97: 561-570. PMID: 39749750, PMCID: PMC11831877, DOI: 10.1002/ana.27141.Peer-Reviewed Original ResearchConceptsEffective anti-seizure medicationDevelopmental delayGain-of-function variantsDevelopmental delay/intellectual disabilitySpike wave activityAnti-seizure medicationsPreponderance of girlsSystematic literature searchOcular involvementMedian ageMusculoskeletal anomaliesClinical spectrumAxial hypotoniaDysmorphic featuresElectroencephalogram abnormalitiesEffects of treatmentClinical manifestationsTreated patientsEpileptic encephalopathyMonoallelic variantsTreatment optionsFrequent findingPhenotypic spectrumVariant p.Epilepsy phenotypePatient-reported outcomes following ciltacabtagene autoleucel or standard of care in patients with lenalidomide-refractory multiple myeloma (CARTITUDE-4): results from a randomised, open-label, phase 3 trial
Mina R, Mylin A, Yokoyama H, Magen H, Alsdorf W, Minnema M, Shune L, Isufi I, Harrison S, Shah U, Schecter J, Vogel M, Lendvai N, Gries K, Katz E, Slaughter A, Lonardi C, Gilbert J, Li Q, Deraedt W, Filho O, Patel N, Florendo E, Karlin L, Weisel K. Patient-reported outcomes following ciltacabtagene autoleucel or standard of care in patients with lenalidomide-refractory multiple myeloma (CARTITUDE-4): results from a randomised, open-label, phase 3 trial. The Lancet Haematology 2025, 12: e45-e56. PMID: 39756844, DOI: 10.1016/s2352-3026(24)00320-x.Peer-Reviewed Original ResearchConceptsLenalidomide-refractory multiple myelomaStandard of careVisual analogue scaleMultiple myelomaGlobal health statusPatient-reported outcomesCiltacabtagene autoleucelIntention-to-treat populationLenalidomide-refractory diseaseProgression-free survivalECOG performance statusPhase 3 trialEORTC global health statusWorsening of symptomsClinically meaningful improvementsEuropean Organisation for ResearchEQ-5D-5L visual analogue scaleCilta-celEuroQol 5-Dimension 5-LevelOpen-labelImmunomodulatory drugsMedian agePerformance statusSecondary endpointsClinical efficacy
2024
Patient Views and Values Placed on the Uterus
Chang O, Huynh A, Ringel N, Hudson P, Halder G, Winkleman W, Ton J, Davidson E, Meriwether K. Patient Views and Values Placed on the Uterus. O&G Open 2024, 1: 048. DOI: 10.1097/og9.0000000000000048.Peer-Reviewed Original ResearchGynecologic conditionsHysterectomy proceduresBenign gynecologic conditionsPelvic organ prolapseProspective cohort studyTreatment of gynecological disordersUterine preservationPelvic painOrgan prolapseMedian agePatient ageUrinary incontinenceChart reviewGynecological disordersCohort studyUterusPatient questionnaireWhite racePatientsMedical CenterHysterectomyPerson-centered careMulticenterGrounded theory approachPhysiological roleThe association between female sex and depression following traumatic brain injury: A systematic review and meta-analysis
Sandhu M, Schonwald A, Boyko M, Jafar T, Freedman I, Woeste J, Kurup A, Funaro M, Zlotnik A, Gruenbaum S, Elsamadicy A, Reynolds R, Gruenbaum B. The association between female sex and depression following traumatic brain injury: A systematic review and meta-analysis. Neuroscience & Biobehavioral Reviews 2024, 168: 105952. PMID: 39603437, DOI: 10.1016/j.neubiorev.2024.105952.Peer-Reviewed Original ResearchPost-TBI depressionTraumatic brain injurySpectrum of TBI severityBrain injuryDiagnosis of depressionNeurobehavioral symptomsTBI severitySystematic reviewDepressionMeta-analysisStatistically significant differenceMedian ageFemale patientsPooled analysisFemale sexRisk factorsSevere casesParticipantsPotential associationSignificant differenceSexSeverityRiskInjurySubjectsImpact of Self-Identified Race on Outcomes in Newly Diagnosed Multiple Myeloma (NDMM) Patients Receiving Induction Therapy with Daratumumab, Lenalidomide, Bortezomib and Dexamethasone (D-RVd)
Joseph N, Gupta S, Kaufman J, Dicamillo S, Roberts D, Gupta V, Hofmeister C, Dhodapkar M, Lonial S, Nooka A. Impact of Self-Identified Race on Outcomes in Newly Diagnosed Multiple Myeloma (NDMM) Patients Receiving Induction Therapy with Daratumumab, Lenalidomide, Bortezomib and Dexamethasone (D-RVd). Blood 2024, 144: 7870-7870. DOI: 10.1182/blood-2024-211988.Peer-Reviewed Original ResearchNewly diagnosed myelomaD-RVdBlack patientsStatistically significant differenceInduction therapyR-ISSOverall survivalMedian ageInternational Myeloma Working Group Uniform Response CriteriaWhite patientsImproved depth of responsePresence of extramedullary diseaseNewly diagnosed multiple myelomaResponse rateMedian overall survivalR-ISS-3Effective induction regimenHigh-risk featuresStem cell transplantationDepth of responseSignificant differenceClinical trial findingsStandard of careHigh-risk classificationMedian PFSClinically Driven Algorithms Identify Patients with Large Granular Lymphocytic Leukemia at Risk of Significant Cytopenia Requiring Treatment
Kiwan A, Kewan T, Bravo-Perez C, Visconte V, Gurnari C, Durmaz A, Siddon A, Halene S, Sethi T, Maciejewski J, Foss F. Clinically Driven Algorithms Identify Patients with Large Granular Lymphocytic Leukemia at Risk of Significant Cytopenia Requiring Treatment. Blood 2024, 144: 4436. DOI: 10.1182/blood-2024-209344.Peer-Reviewed Original ResearchT-cell rearrangementArea under the curveGranular lymphocytic leukemiaMonoclonal gammopathyUnivariate analysisRheumatoid arthritisMyelodysplastic syndromeClonal hematopoiesisMedian ageLymphocytic leukemiaFactors associated with anemiaAbsence of CD4Associated with cytopeniaHistory of rheumatoid arthritisAssociated with neutropeniaExpression of CD5Presence of splenomegalyTreatment requirementsAssociated with anemiaMultivariate logistic regression modelPrimary etiological factorMultivariate regressionPersonalized treatment strategiesUnivariate logistic regressionAssociated with treatmentIdentifying Patients with Erythrocytosis Not Requiring JAK2 Testing: External Validation and Decision Analysis of the Jakpot Prediction Rule
Lam B, Ito S, Ryu J, O'Sullivan K, Potnis K, Lu R, Bidikian A, Freed J, La J, Goshua G. Identifying Patients with Erythrocytosis Not Requiring JAK2 Testing: External Validation and Decision Analysis of the Jakpot Prediction Rule. Blood 2024, 144: 3669-3669. DOI: 10.1182/blood-2024-198033.Peer-Reviewed Original ResearchNegative predictive valueBeth Israel Deaconess Medical CenterClinical prediction rulePolycythemia veraIncremental net monetary benefitHealth resource utilizationPV patientsMyeloproliferative neoplasmsVA cohortTest characteristicsUS health system perspectivePrediction ruleAssociated with increased riskNon-fatal cardiovascular eventsExternal validation cohortAssociated with increased risk of strokeRandomized trial dataMarkov cohort modelLifetime time horizonProbabilistic sensitivity analysesRisk of strokePersistent erythrocytosisMedian ageHematologic malignanciesDiagnostic workupChanges in Red Blood Cell Transfusion Burden with Luspatercept Versus Epoetin Alfa in Patients with Lower-Risk Myelodysplastic Syndromes in the Phase 3, Open-Label, Randomized, Controlled COMMANDS Trial
Garcia-Manero G, Della Porta M, Santini V, Zeidan A, Komrokji R, Fenaux P, Valcárcel D, Shortt J, Glassberg M, Yucel A, Lai Y, Miteva D, Rose S, Hnoosh A, Platzbecker U. Changes in Red Blood Cell Transfusion Burden with Luspatercept Versus Epoetin Alfa in Patients with Lower-Risk Myelodysplastic Syndromes in the Phase 3, Open-Label, Randomized, Controlled COMMANDS Trial. Blood 2024, 144: 1832-1832. DOI: 10.1182/blood-2024-198304.Peer-Reviewed Original ResearchRegular red blood cell transfusionsLower-risk myelodysplastic syndromesErythropoiesis-stimulating agentsTreated with epoetin alfaEpoetin alfaRBC unitsLuspatercept treatmentTransfusion burdenMyelodysplastic syndromeOpen-labelFirst-in-class erythroid maturation agentRed blood cell transfusion burdenEfficacy of erythropoiesis-stimulating agentsRed blood cell transfusionErythroid maturation agentBlood cell transfusionBaseline Hb levelsArm of treatmentRBC-TICell transfusionMedian ageResponse durabilityChronic anemiaHb levelsLuspaterceptUsing Phosphatidylethanol as an Adjunct to Self-Reported Alcohol Use Improves Identification of Liver Fibrosis Risk.
Murnane P, Afshar M, Chamie G, Cook R, Ferguson T, Haque L, Jacobson K, Justice A, Kim T, Khalili M, Krupitsky E, McGinnis K, Molina P, Muyindike W, Myers B, Richards V, So-Armah K, Stewart S, Sulkowski M, Tien P, Hahn J. Using Phosphatidylethanol as an Adjunct to Self-Reported Alcohol Use Improves Identification of Liver Fibrosis Risk. The American Journal Of Gastroenterology 2024 PMID: 39480054, DOI: 10.14309/ajg.0000000000003178.Peer-Reviewed Original ResearchLiver fibrosis riskAUDIT-CFIB-4Self-reported alcohol useOdds ratioAlcohol useFibrosis riskPooled individual-level dataLiver fibrosis preventionBody mass indexAssessment of alcohol useManagement of liver diseaseOne-unit differenceIndividual-level dataMedian ageAUDIT-C.Mass indexSuppression statusLiver diseaseFibrosis preventionBlood concentrationsAdjusted modelsLogistic regressionCategorical variablesHIV
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply